Why did compounded tirzepatide exist in the first place?
Tirzepatide — the active molecule in Eli Lilly’s branded products Mounjaro and Zepbound — was placed on the FDA drug shortage list in 2022 because commercial supply could not keep up with the surge in prescriptions that followed approval. For roughly two years, that listing was the backdrop to everything written about compounded tirzepatide.
The compounded market grew substantially over those years. 503A pharmacies (which prepare individual prescriptions) and 503B outsourcing facilities (which produce larger batches) both had tirzepatide in their workload, and patients found the compounded route easier to reach and often cheaper than the branded version.
What did the FDA actually decide about compounded tirzepatide in late 2024?
In late 2024, the FDA determined that the tirzepatide shortage had been resolved — meaning Eli Lilly had sufficiently increased supply to meet national demand. Compounding that had been running on the strength of that shortage was then wound down.
Specifically, the FDA directed 503B outsourcing facilities to stop producing tirzepatide on that basis and gave a wind-down period for compliance. The ruling drew more attention for 503B facilities (large-batch producers) than for 503A pharmacies, because 503B compounding had scaled to a size that represented a direct commercial threat to the branded product.
The media and social-media framing — “compound tirzepatide is banned” — overstated the ruling. What closed was the broad, shortage-era route into bulk 503B production. Compounding for one identified patient under 21 U.S.C. §353a is a separate provision, and it carried on subject to the standard rules of that statute.
The word “banned” did a lot of work the decision never did. A prescription with one patient’s name on it is still how a 503A pharmacy fills tirzepatide.
How does 503A compounding still work?
Under 21 U.S.C. §353a, a 503A pharmacy may compound a drug for an identified individual patient based on a valid prescription, provided the compounded product differs in some way from the commercially available product — for example, a different dosage strength, an excluded allergen, or a formulation the commercial product does not offer.
This is a meaningful distinction. A patient who has a documented clinical reason to use a compounded tirzepatide formulation — and whose prescriber provides a valid prescription establishing that clinical basis — can still receive compounded tirzepatide from a 503A pharmacy. The patient-specific prescription pathway was not closed by the 2024 decision.
What has changed is the weight the documentation carries. In the years when supply was the whole story, the paperwork question rarely came up. Today the individual clinical relationship and the specific rationale for a compounded preparation over the commercial product are the parts that matter, which is one reason it is worth knowing what is in your vial: PepScribe’s tirzepatide vials pair the molecule with cyanocobalamin, at a strength written for the individual patient.
What does this mean for patients right now?
If you were receiving compounded tirzepatide through a legitimate 503A pharmacy with a valid prescription and have an ongoing clinical relationship with your prescriber, your access pathway has not been categorically terminated. Whether your specific pharmacy and prescriber relationship meets the current standard is a clinical and legal question — not one this article can answer for your individual situation.
What you should be cautious of:
- Gray-market and overseas vendors: These sources operate outside the FDA oversight framework regardless of shortage status. Purity, sterility, and accurate dosing are unverifiable. The regulatory change does not make these sources more legitimate — it makes the gap between regulated and unregulated sources starker.
- Telehealth platforms that have gone quiet: Some compounding-heavy telehealth platforms scaled rapidly during the shortage window and are now navigating a significantly changed regulatory environment. If your platform has stopped communicating or become harder to reach, that is a signal to evaluate your options.
- Misleading “still legal” marketing: Vendors who confidently claim full access with no caveats, and no explanation of the compounding basis for that access, deserve skepticism. The regulatory landscape is genuinely nuanced, and blanket “nothing has changed” claims are not supported by the FDA’s public guidance.
PepScribe’s approach: USA 503A compounding only
PepScribe uses licensed 503A compounding pharmacies based in the United States for all tirzepatide prescriptions. Our pharmacy partners compound patient-specific formulations under state pharmacy board oversight and USP quality standards.
We do not use 503B outsourcing facilities for tirzepatide. We do not source from overseas suppliers or gray-market vendors. No hidden overseas supply chain — that is not a marketing phrase for us, it is the operational standard we hold our pharmacy partners to.
Every tirzepatide prescription through PepScribe is issued by a licensed clinician following a clinical review of your intake information. What the compounded preparation rests on is that prescriber-patient relationship, the clinical rationale it establishes, and the prescription written in your name.
Frequently asked questions
Is compound tirzepatide banned in the US?
FDA determined the tirzepatide shortage had resolved in late 2024 and told compounding pharmacies to stop compounding it on the basis of shortage status. The coverage that followed reached for the word ban, which is broader than what the decision did. Compounded tirzepatide is prepared for one named patient against a prescription from a licensed clinician, filled by a licensed 503A pharmacy in the USA, and it is not FDA-approved. Whether it suits your case is something your clinician works out with you.
Can I still get compounded tirzepatide?
Yes. Compounded tirzepatide is dispensed through licensed 503A pharmacies against a prescription written for one individual patient by a licensed clinician, and it is not an FDA-approved finished drug. PepScribe fills through a licensed 503A pharmacy in the USA; its preparation combines tirzepatide with cyanocobalamin, dosed for the patient it was written for. Your clinician can tell you what applies to your own prescription.
What is the difference between 503A and 503B compounding for tirzepatide?
503A pharmacies compound individual prescriptions for specific patients under a prescriber-patient relationship. 503B outsourcing facilities produce larger batches for broader distribution and are FDA-registered. The FDA ruling that restricted tirzepatide compounding focused on the bulk 503B production the shortage era had supported. 503A patient-specific compounding operates under a different statutory framework.
Should I be worried that tirzepatide compounding will be fully blocked?
The regulatory landscape for compounded GLP-1 drugs continues to evolve. The most responsible approach is to work with a licensed clinician and a pharmacy partner that operates squarely within 503A statutory requirements. Avoid "peptide vendor" websites and gray-market sources, which carry meaningful purity, sterility, and legal risk whatever the regulatory picture looks like in a given year.
Does the shortage ruling affect branded Mounjaro or Zepbound?
No. The FDA shortage ruling and subsequent compounding restrictions apply to compounding pharmacies, not to the branded products Mounjaro (for type 2 diabetes management) and Zepbound (for chronic weight management), which are FDA-approved and commercially distributed through standard pharmacy channels.
